Drug Profile
Zimberelimab - Arcus Biosciences/Guangzhou Gloria Biosciences/Taiho Pharmaceutical
Alternative Names: AB 122; GLS 010; GS-0122; WBP 3055; YUTUOLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator WuXi Biologics
- Developer Arcus Biosciences; Gilead Sciences; Guangzhou Gloria Biosciences; Memorial Sloan-Kettering Cancer Center; Strata Oncology; Taiho Pharmaceutical; UCLAs Jonsson Comprehensive Cancer Center; University of Texas Southwestern Medical Center; Yale University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cervical cancer; Hodgkin's disease
- Phase III Gastrointestinal cancer; Non-small cell lung cancer
- Phase II Biliary cancer; Liposarcoma; Liver cancer; Malignant melanoma; Rectal cancer
- Phase I/II Colorectal cancer; Pancreatic cancer; Solid tumours
- Phase I Cancer; Glioblastoma
- Discontinued Prostate cancer
Most Recent Events
- 01 Feb 2024 Arcus Biosciences terminates a phase-I/II trial in Adenocarcinoma (Combination therapy, Late-stage disease, Inoperable/Unresectable, First-line therapy) and Pancreatic cancer (Combination therapy, First-line therapy, Late-stage disease) in USA (IV) due to early accrual (NCT05688215)
- 27 Oct 2023 Arcus Biosciences in collaboration with Vanderbilt-Ingram Cancer Center withdraws a phase Ib PANTHEoN trial in Head and neck cancer (Late-stage disease, Combination therapy) (PO), prior to enrolment due to funding (NCT04892875)
- 06 Oct 2023 Arcus Biosciences completes enrolment in the phase I/II ARC-9 trial for Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA, France, Italy, South Korea, Spain and UK (PO) (NCT04660812)